hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06361303 id: PS230001 id: PS230001 / PSS001 type: OTHER domain: US FDA briefTitle: The Happiest Baby, Inc. SNOO Postmarket Surveillance Study overallStatus: RECRUITING date: 2023-11-29 date: 2025-09 date: 2025-09 date: 2024-04-11 date: 2024-04-11 name: Happiest Baby, Inc. class: INDUSTRY briefSummary: This postmarket surveillance study will evaluate the safety of the SNOO Smart Sleeper Bassinet when used for infants who are at high risk for Sudden Unexpected Infant Death (SUID). This study will survey 1000 caregivers of high-risk infants to examine the frequency of death or serious injury occurring in the SNOO Bassinet. conditions: Infant Death conditions: Serious Injury studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1000 type: ESTIMATED name: SNOO Bassinet measure: Serious Injury measure: Infant death measure: Infant age during SNOO use measure: Degree of SNOO use measure: Weaning rationale sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Happiest Baby, Inc. status: RECRUITING city: Los Angeles state: California zip: 90064 country: United States name: Christopher Laine, PhD role: CONTACT phone: 310-476-4440 email: christopher@happiestbaby.com name: Sarah Chang, MPH role: CONTACT phone: 310-476-4440 email: schang@happiestbaby.com name: Christopher Laine, PhD role: PRINCIPAL_INVESTIGATOR lat: 34.05223 lon: -118.24368 hasResults: False
nctId: NCT06361290 id: APHP231703 briefTitle: Diaphyseal Reconstruction of Malignant Tumors in Children acronym: RDTM overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-10 date: 2024-10 date: 2024-04-11 date: 2024-04-11 name: Assistance Publique - Hôpitaux de Paris class: OTHER briefSummary: Primary malignant bone tumors represent 5% of malignant tumors in children, 90% of which are osteosarcomas or Ewing sarcomas.
The aim of the present research is to compare the three techniques concerning the consolidation aspect, the reoperation rates, the rates of bone complications, septic, and the functional results by the study of the medical files of approximately 90 patients operated between 1986 and 2017. conditions: Childhood Malignant Tumors of Lower Limbs studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 90 type: ESTIMATED name: Data collection from hospital medical records measure: Duration of bone consolidation period measure: Rate of surgical re-intervention measure: Short- and long-term complication rates measure: Long-term functional results measure: Relationship between radiotherapy and biological reconstruction result sex: ALL maximumAge: 17 Years stdAges: CHILD facility: Hôpital Armand-Trousseau city: Paris zip: 75012 country: France name: Franck Fitoussi, MD-PhD role: CONTACT phone: 679693634 phoneExt: +33 email: franck.fitoussi@trs.aphp.fr lat: 48.85341 lon: 2.3488 facility: Hôpital Necker-Enfants Malades city: Paris zip: 75015 country: France name: Edouard Haumont, MD role: CONTACT phone: 486587192 phoneExt: +32 email: edouard.haumont@.aphp.fr lat: 48.85341 lon: 2.3488 hasResults: False
nctId: NCT06361277 id: JW22104 briefTitle: To Evaluate the Pharmacokinetic Characteristics and Safety in Healthy Volunteers overallStatus: COMPLETED date: 2023-11-03 date: 2023-11-20 date: 2023-11-27 date: 2024-04-11 date: 2024-04-11 name: JW Pharmaceutical class: INDUSTRY briefSummary: The objective is to evaluate the safety and pharmacokinetic characteristics after co-administration of JW0202 and C2202 and co-administration of C2205 and JW0201 in healthy volunteers under fasting conditions conditions: Healthy studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: OTHER masking: NONE count: 56 type: ACTUAL name: Reference Drug or Test Drug measure: AUCt measure: Cmax sex: ALL minimumAge: 19 Years maximumAge: 55 Years stdAges: ADULT facility: Clinical Trial Center, Jeonbuk National University Hospital city: Jeonju country: Korea, Republic of lat: 35.82194 lon: 127.14889 hasResults: False
nctId: NCT06361264 id: Karanahan briefTitle: Clinical Study of Personalized Chemotherapy for Breast Cancer With Low Doses of Cyclophosphamide overallStatus: RECRUITING date: 2018-11-01 date: 2024-12-01 date: 2025-12-01 date: 2024-04-11 date: 2024-04-11 name: KARANAHAN class: OTHER briefSummary: The goal of this study is to evaluate the safety and clinical efficacy of personalized chemotherapy with low doses of cyclophosphamide administered taking into account the reparative cycle of tumor cells in participants with breast cancer (stage IV or disease progression). The main question it aims to answer is: Does personalized chemotherapy of breast cancer with low doses of cyclophosphamide, taking into account the reparative cycle of tumor cells, lead to a significant reduction in tumor size and improvement in the visual status of controlled tumor foci relative to their initial state? During the preparatory stage, a tumor sample from participant is harvested intraoperatively. The primary culture is obtained from this tumor tissue sample. Repair cycle time is estimated, and the day when tumor cells are synchronized at the cell cycle G2/M phase is identified. The schedule of administering cyclophosphamide and DNAmix complex composite preparation is calculated according to the resulting time points. According to the elaborated regimen, the participant receives 4 intravenous cyclophosphamide injections at the dose of 300 mg/m2 in combination with 4 injections of 1-12 mg of DNAmix administered into prominent tumor nidi and lymph depots. The participant receives from 2 to 6 courses of therapy. The interval between courses is 21 days. conditions: Stage IV Breast Cancer studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: Karanahan measure: The size of tumor foci measure: The quality of life score measure: The immunomodulatory effect sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Karanahan Llc status: RECRUITING city: Novosibirsk state: Novosibirsk Region zip: 630090 country: Russian Federation name: Anastasia Proskurina role: CONTACT email: labmolbiol@mail.ru name: Sergey Sidorov role: PRINCIPAL_INVESTIGATOR lat: 55.0415 lon: 82.9346 hasResults: False
nctId: NCT06361251 id: CS5_10 briefTitle: Interventional, Monocentric, Double-blind Randomized Category 2b Study Evaluating the Evaluation of the Tolerance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots (Solar and Senile Lentigines, Post -Inflammatory Hyperpigmentation (Pih)) on the Face acronym: CS5_10 overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-12 date: 2024-12 date: 2024-04-11 date: 2024-04-17 name: Cryonove Pharma class: INDUSTRY name: Dermatech briefSummary: The goal of this clinical trial is to compare the 2 different prototype of cytoselectivecryotherapy devices (name of the devices : CRYONOVE) use in brown spots on the face of subject from different ethnicities. The main questions it aims to answer are:
Researchers will compare the tolerance and performance of the 3 prototypes. conditions: Lentigo conditions: Solar Lentigo conditions: Post Inflammatory Hyperpigmentation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Proof of concept study concerning 2 prototypes of cyto-selective cryotherapy devices corresponding to a modified CE marked medical device (ref: 822-v1). primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Double blind (participant and care provider) whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 30 type: ESTIMATED name: CRYONOVE (EC14_4osc) name: CRYONOVE (EC05osc) measure: Tolerance measure: Performance (Acquisitions C-cube) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: SMU - Photobiology Laboratory, Sefako Makgatho Health Sciences University city: Pretoria country: South Africa lat: -25.74486 lon: 28.18783 hasResults: False
nctId: NCT06361238 id: 2023-LCYJ-PY-21 briefTitle: Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2026-03-31 date: 2027-03-31 date: 2024-04-11 date: 2024-04-11 name: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School class: OTHER briefSummary: This study aims to clarify the preventive effect of perioperative liraglutide application on postoperative delirium in elderly patients with Type 2 diabetes undergoing cardiac surgery. conditions: Delirium, Postoperative studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 260 type: ESTIMATED name: Liraglutide injection name: Placebo injection measure: The incidence of delirium measure: The severity of delirium measure: Cognitive function measure: Anxiety measure: Depression measure: Duration of ICU stay measure: Mechanical ventilation time measure: Duration of hospital stay measure: In-hospital mortality measure: Incidence of adverse events measure: Rate of major cardiovascular adverse events measure: Serum levels of NSE measure: Serum levels of CRP measure: Serum levels of IL-1α measure: Serum levels of TNF-α measure: Serum levels of C3 measure: Serum levels of LDH measure: Serum levels of CK measure: Serum levels of CK-MB measure: Serum levels of AST measure: Serum levels of cTNT measure: Serum levels of BNP measure: Serum levels of C1q measure: Serum levels of IL-1β measure: Serum levels of IL-6 measure: Serum levels of S100β measure: Left Ventricular Posterior Wall Thickness in Diastole (LVPWTd) measure: Left Ventricular End-Diastolic Dimension (LVDd) measure: Left Ventricular End-Systolic Diameter (LVDs) measure: Left Atrial Diameter (LAD) measure: Ejection Fraction (EF) measure: Fractional Shortening (FS) measure: Early Diastolic Velocity/Atrial Diastolic Velocity (E/A) measure: Interventricular Septum Thickness in Diastolic (IVSTd) sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06361225 id: 0075-24-MMC briefTitle: Routine Use of RUSH Protocol in the Intensive Care Unit overallStatus: NOT_YET_RECRUITING date: 2024-08-01 date: 2025-08-01 date: 2025-08-01 date: 2024-04-11 date: 2024-04-11 name: Meir Medical Center class: OTHER briefSummary: The RUSH protocol has been used for several years for the rapid evaluation of a patient admitted to the emergency room with shock. Traditionally, its use was especially common in trauma victims, but later its use was extended to patients admitted to the emergency room with shock from any reason. The protocol includes rapid assessment with the guideness of ultrasound of heart contraction, assessment for pleural effusions, assessment of intra-abdominal blood (FAST), diagnosis of venous thrombosis (DVT), and rulling out hydronephrosis. It can also add a pupil size assessment and an evaluation of the gallbladder and bile ducts, as well as the size of the bladder. In intensive care, we use this protocol (or part of it) for the evaluation of a patient who is deteriorating in the ICU for an unknown reason . In some patients we use this protocol as a routine part of the physical examination as part of the daily patient evaluation.
We would like to investigate whether the routine use of the RUSH protocol as part of the daily patient evaluation in the general intensive care unit will lead to any change in the patient's management. conditions: RUSH Protocol studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 50 type: ESTIMATED name: evaluation with RUSH protocol measure: Change of patient medical therapy measure: Performing unplanned laboratory tests measure: Performing unplanned image tests measure: Performing unplanned invasive procedure sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Meir Medical Center city: Kfar Saba country: Israel lat: 32.175 lon: 34.90694 hasResults: False
nctId: NCT06361212 id: BJXH-2022-002 briefTitle: Ethoximod Pharmacokinetics In Healthy Subjects overallStatus: COMPLETED date: 2022-09-01 date: 2022-09-20 date: 2024-01-12 date: 2024-04-11 date: 2024-04-11 name: Longevity Inc. class: INDUSTRY briefSummary: The goal of this clinical trial is to evaluate the tolerability, pharmacokinetics and pharmacodynamics of Ethoximod in healthy subjects. The main questions it arms to answer are:
3. to evaluate of the effect of food on the pharmacokinetics of Ethoximod in healthy subjects Participants will receive test tablets or placebo at the indicated date and collect blood samples. conditions: Psoriasis studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 65 type: ACTUAL name: Ethoximod measure: Peak plasma concentration (Cmax) measure: Time to peak plasma concentration (Tmax) measure: The lowest plasma concentration (Cmin) measure: Half-life (t1/2) measure: Number of adverse events and number of participants with adverse events measure: Lymphocyte count measure: Percentage of CD3+CD4+ and CD3+CD8+ T cells sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: The first hospital of Jilin University city: Changchun state: Jilin country: China lat: 43.88 lon: 125.32278 hasResults: False
nctId: NCT06361199 id: BJXH-2021-001 briefTitle: Proximod Pharmacokinetics in Healthy Subjects and Patients With Rheumatoid Arthritis overallStatus: COMPLETED date: 2021-12-16 date: 2022-02-16 date: 2023-10-08 date: 2024-04-11 date: 2024-04-19 name: Longevity Inc. class: INDUSTRY briefSummary: The goal of this clinical trial is to evaluate the tolerability, pharmacokinetics and pharmacodynamics of Proximod in healthy subjects and patients with rheumatoid arthritis. The main questions it arms to answer are:
Participants will receive test tablets or placebo at the indicated date and collect blood samples. conditions: Rheumatoid Arthritis studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 22 type: ACTUAL name: Proximod name: Placebo measure: Peak plasma concentration (Cmax) measure: Time to peak plasma concentration (Tmax) measure: The lowest plasma concentration (Cmin) measure: Half-life (t1/2) measure: Area under the plasma concentration versus time curve (AUC) measure: Number of adverse events and number of participants with adverse events measure: Lymphocyte count measure: Percentage of CD3+CD4+ and CD3+CD8+T cells measure: ACR20 score in Patients With Rheumatoid Arthritis measure: Disease Activity Score（DAS28-CRP）in Patients With Rheumatoid Arthritis sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The first hospital of Jilin University city: Changchun state: Jilin country: China lat: 43.88 lon: 125.32278 hasResults: False
nctId: NCT06361186 id: BJXH-2017-001 briefTitle: Proximod Pharmacokinetics In Healthy Subjects overallStatus: COMPLETED date: 2017-09-14 date: 2017-11-01 date: 2021-06-22 date: 2024-04-11 date: 2024-04-11 name: Longevity Inc. class: INDUSTRY briefSummary: The goal of this clinical trial is to evaluate the tolerability, pharmacokinetics and pharmacodynamics of Proximod in healthy subjects. The main questions it arms to answer are:
3. to evaluation of the effect of food on the pharmacokinetics of Proximod in healthy subjects Participants will receive test tablets or placebo at the indicated date and collect blood samples. conditions: Rheumatoid Arthritis studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 134 type: ACTUAL name: Proximod name: Placebo measure: Peak plasma concentration (Cmax) measure: Time to peak plasma concentration (Tmax) measure: The lowest plasma concentration (Cmin) measure: Half-life (t1/2) measure: Number of adverse events and number of participants with adverse events measure: Lymphocyte count measure: Percentage of CD3+CD4+ and CD3+CD8+ T cells sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: The first hospital of Jilin University city: Changchun state: Jilin country: China lat: 43.88 lon: 125.32278 hasResults: False
nctId: NCT06361173 id: STUDY00004127 briefTitle: Spanish BMT4me Usability & Acceptability overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2026-05-01 date: 2026-05-01 date: 2024-04-11 date: 2024-04-11 name: Nationwide Children's Hospital class: OTHER name: Columbia University briefSummary: The objective of this project is to trans-create, conduct user testing of a previously developed and piloted mHealth app, and user acceptability with parents of children in the acute phase post-allogeneic hematopoietic stem cell transplant (HSCT). Nationwide Children's Hospital (NCH) will be the primary data collection site and Columbia University Irving Medical Center will be a secondary site. conditions: Bone Marrow Transplant studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 30 type: ESTIMATED name: BMT4me measure: Assess app usability using the System Usability Scale (SUS) sex: ALL minimumAge: 0 Years maximumAge: 17 Years stdAges: CHILD facility: Columbia University Irving Medical Center city: New York state: New York zip: 10027 country: United States name: Melissa Beauchemin role: CONTACT email: mmp2123@cumc.columbia.edu lat: 40.71427 lon: -74.00597 facility: Nationwide Children's Hospital city: Columbus state: Ohio zip: 43215 country: United States name: Bianca Franklin, BS role: CONTACT name: Micah Skeens, PhD role: PRINCIPAL_INVESTIGATOR lat: 39.96118 lon: -82.99879 hasResults: False
nctId: NCT06361160 id: D23-P037 briefTitle: Reduction of Auditory-Verbal Hallucinations in Schizophrenia Through Cortical Neuromodulation acronym: HALLUSTIM overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-04 date: 2026-04 date: 2024-04-11 date: 2024-04-11 name: Centre Hospitalier St Anne class: OTHER briefSummary: Approximately 1% of the general population will be affected by schizophrenia over the course of their lives, with life expectancy being reduced by 20 years on average and quality of life being severely diminished in affected individuals. One third of patients suffering from schizophrenia will evolve towards a resistant form of the disease, amongst which many will suffer from auditory-verbal hallucinations (AVH) that current therapeutic approaches struggle to alleviate. Previous work from our team has demonstrated the possibility of robustly inferring the periods of occurrence of AVH from fMRI data, paving the way for the development of a closed-loop neuromodulation system comprised of an electrode array positioned in Broca's area, which would detect AVH in real time, and effector electrodes which would stimulate the temporo-parietal cortex to interrupt them. The aim of this project is to assess the feasibility of this system. To do so, we will first test the ability of transcranial magnetic stimulation of the "continuous theta burst" (cTBS) type, applied at the time of AVH onset, to reduce their duration and intensity, and assess whether this is associated with therapeutic response to the current gold standard rTMS protocol for AVH reduction through neuroplasticity induction. Demonstrating the feasibility of acute suppression of AVH by cortical neurostimulation is an essential element in the feasibility of a closed-loop reactive neuromodulation system.
Phase 2: open-label study offering patients a routine rTMS protocol which has demonstrated its effects on AVH (10 TMS sessions over one workweek - twice daily with 1-hour intervals, MULTIMODHAL study, NCT01373866). conditions: Treatment Resistant Schizophrenia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Patients (20) suffering from resistant schizophrenia will be enrolled over a 12-month period and will be randomized in a (1:1) ratio to start with either active or sham Transcranial Magnetic Stimulation (TMS) for the first of their 12 sessions, which will then alternate from one condition to the other for each patient. primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: Only the person conducting the experiment will know which condition each patient is in. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 20 type: ESTIMATED name: Active Transcranial Magnetic Stimulation (TMS) name: Sham Transcranial Magnetic Stimulation (TMS) measure: Duration of auditory-verbal hallucinations measure: Clinical scales scores measure: Measure of the duration and/or intensity of HAV (in seconds) during active phasic stimulation sessions compared to sham sessions (phase 1) among TMS responders and non-responders in phase 2 measure: Intensity of auditory-verbal hallucinations sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06361147 id: 3764/2-10-2019 briefTitle: Psychoeducation of Adult Siblings of ASD People (Autism Spectrum Disorder). overallStatus: ACTIVE_NOT_RECRUITING date: 2024-03-28 date: 2024-07 date: 2024-10 date: 2024-04-11 date: 2024-04-11 name: Hellenic Mediterranean University class: OTHER briefSummary: The aim of this study is to apply a psychoeducational program in adult siblings of people with ASD as a means to provide knowledge related to the disorder and improving their quality of life.
Participation in this program is expected to contribute in the improvement of the quality of life of the participants, their siblings with ASD and those related to them. No risk is identified. conditions: Autism Spectrum Disorder conditions: Sibling Relations studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Interventional groups and Control groups primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: PARTICIPANT count: 88 type: ACTUAL name: Cygnet program for ASD measure: Psychoeducation effectiveness on siblings of ASD measure: Psychoeducation effectiveness on the knowledge of ASD measure: Psychoeducation effectiveness on siblings relationship measure: Psychoeducation effectiveness on resilience of siblings of ASD measure: Psychoeducation effectiveness on the well-being of siblings of ASD sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Hellenic Mediterranean University city: Heraklion state: Crete zip: 82102 country: Greece lat: 35.32787 lon: 25.14341 hasResults: False
nctId: NCT06361134 id: 14574941-302,08,01- briefTitle: Efficacy of Supporting SAFE Early Intervention overallStatus: COMPLETED date: 2021-01-15 date: 2022-05-15 date: 2022-11-15 date: 2024-04-11 date: 2024-04-11 name: Gazi University class: OTHER briefSummary: Within the scope of the study, it was planned that risky babies would be treated with the SAFE early intervention approach for 10 weeks after they were discharged from the intensive care unit. Neurodevelopmental Treatment was applied to the control group. Sensory, motor and language development of the babies were evaluated before and after the intervention. conditions: Infant Development conditions: Physiotherapy conditions: Early Intervention studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 26 type: ACTUAL name: SAFE Early İntervention name: NDT based therapy measure: Test of Infant Motor Profile measure: Bayley Scales of Infant and Toddler Development, Third Edition, measure: Infant/Toddler Sensory Profile 2 measure: Infant/Toddler HOME Inventory sex: ALL minimumAge: 1 Month maximumAge: 3 Months stdAges: CHILD facility: Erzurum Technical University city: Erzurum country: Turkey lat: 39.90861 lon: 41.27694 hasResults: False